

## ASX RELEASE



ASX Code: ESE

29 March 2018

### **CHAIRMAN'S ADDRESS ANNUAL GENERAL MEETING – 29 March 18 eSense-Lab Ltd**

On behalf of the Board of Directors, I would like to welcome you to the **eSense-Lab Limited's** ("eSense" or the "Company") (ASX: ESE) Annual General Meeting for 2017.

eSense has the honour of being the first Israeli Incorporated Company to list on the Australian Stock Exchange ("ASX"), on 14 February 2017, following a successful oversubscribed IPO capital raising.

Rather than discussing the legal proceedings and director investigation, I would like to focus on a review of what has been achieved since the IPO.

During this period, the Company focused on development and upgrade of its plant profiling technology. eSense technology "reverse engineers" rare or high-value plants, and reconstructs the terpene profile of that plant, using alternate natural sources, in a more cost-effective and sustainable way.

Terpenes are naturally occurring compounds which account for the flavour and fragrance of plants. eSense's technology creates a reconstructed terpene profile replicates the flavour, fragrance and other desired characteristics of the targeted plant to a similarity of 99.9%.

eSense's initial focus has been on the cannabis plant, however future high-value target plants include ginseng, saffron and other medicinal plants and spices.

eSense is very proud of technology achievements and unique breakthroughs that have been made in the past year. eSense continually achieves new research and development heights with abilities to significantly strength our IP, as well as entering new opportunities in across revenue-generating markets. Including the recently announced clear anti-inflammatory and antioxidant activity with the Company's terpenes strains.

In Israel, eSense has recently commissioned a new R+D laboratory. Israel is regarded as the global leader in medical cannabis research, due to the fact that it has the highest number of PHD's per capita in the world and has a very favourable regulatory climate for doing serious scientific research. Israeli scientists are leading in the field of cannabis genetics with a rich IP bank of cannabis patents.

Marketing-wise, we've approached various markets and signed significant MOU and Joint Venture agreements to assure we continue to generate revenue in the years to come.

eSense's achievements during the past year included:

- Sales to Allor Vaporizers
- Binding sales agreement with Singapore ATM for distribution of eSense's product line in Singapore, valued a minimum of US\$540,000 in the first 12 months
- Binding sales agreement with IC Access to develop products for the United Arab Emirates market (announced in January 2018)
- Joint Ventures with two beer manufacturers – Young Henry's in Australia and Progressive Brands which has a brewery in Greece (announced in January 2018)
- Production of first prototype of terpene-infused chocolate in the USA
- Opening of new research and customer support facilities in Israel.

eSense has successfully raised over A\$1.6m since the IPO from sophisticated investors and has received a binding commitment from an investor for a strategic investment of A\$500,000.

I would like to thank our Shareholders for your support in these activities.

It has been a few months since I have taken over as Chairman, having taken over from Brendan de Kauwe in February 2018, and I thank my fellow Board members for their support over the past year. I also thank our Management team, R+D team and staff for their efforts as we have worked to successfully to advance the Company.

With a growing customer base and the agreements eSense has entered into since the start of the 2017 financial year, the Company is confident of generating revenue and delivering value to its shareholders. The Company expects to make further developments using its cannabis technology in 2018 as the medicinal cannabis industry continues to grow.

---

**FOR FURTHER INFORMATION:**

Company Secretary

Ian Pamensky  
+61 414 864 746  
[ian@cfo2grow.com.au](mailto:ian@cfo2grow.com.au)

Investor/media relations

Matthew Wright  
+61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**About eSense-Lab**

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost

To learn more about eSense-Lab, visit [www.esense-lab.com](http://www.esense-lab.com)